Syndax Pharmaceuticals SNDX Return on invested capital
Return on invested capital at other companies
Other financials
Where this comes from
Calculated from Syndax Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's return on invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's return on invested capital?
- Syndax Pharmaceuticals (SNDX) reported return on invested capital of -67.9% in Q1 2026.
- How has Syndax Pharmaceuticals's return on invested capital changed year-over-year?
- Syndax Pharmaceuticals's return on invested capital increased by 23.4% year-over-year, from -88.6% to -67.9%.
- What is the long-term trend for Syndax Pharmaceuticals's return on invested capital?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's return on invested capital has grown at a -12.6% compound annual growth rate (CAGR), from -98.3% to -50.3%.
- What does return on invested capital mean?
- Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.